Streetbeat News

Analyst Ratings

INMB

Raymond James has initiated coverage on INmune Bio (NASDAQ:INMB) with an Outperform rating and set a price target of $18.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 5:11 pm

EME

GE

MPWR

PDD

VST

Benzinga's Stock Whisper Index highlights five stocks that are gaining interest among investors. Monolithic Power Systems saw a price target increase from Stifel, EMCOR Group is anticipated to benefit from a Fed rate cut, PDD Holdings is boosted by Chinese monetary stimulus, Vistra Corp is gaining from energy sector interest, and GE Aerospace is launching an AI initiative with Microsoft.

Portfolio Pulse from Chris Katje

September 27, 2024 | 5:10 pm

LENZ

Raymond James has initiated coverage on LENZ Therapeutics with an Outperform rating and set a price target of $37.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 5:09 pm

ACHV

Raymond James has initiated coverage on Achieve Life Sciences with a Strong Buy rating and set a price target of $20.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 5:06 pm

CERT

Certara (NASDAQ:CERT) has received mixed analyst ratings over the past three months, with a recent average price target of $17.5, down from $19.50. Analysts have adjusted their ratings and price targets in response to market conditions, reflecting a range of perspectives from bullish to bearish. Certara's financial performance shows a 3.17% revenue growth, a net margin of -13.48%, and a debt-to-equity ratio of 0.3.

Portfolio Pulse from Benzinga Insights

September 27, 2024 | 5:01 pm

PHR

Phreesia (NYSE:PHR) has received diverse analyst ratings over the past three months, with a mix of bullish and somewhat bullish sentiments. The average 12-month price target has slightly increased to $29.00. Analysts have adjusted their ratings and price targets, reflecting their responses to Phreesia's recent performance and market conditions. Phreesia has shown strong revenue growth and effective debt management, but faces challenges with net margin and asset utilization.

Portfolio Pulse from Benzinga Insights

September 27, 2024 | 5:01 pm

LXRX

Lexicon Pharmaceuticals (NASDAQ:LXRX) has received 7 analyst ratings in the past three months, all of which are bullish. The average 12-month price target is $10.00, with no changes in recent months. The company has shown significant revenue growth but faces challenges with negative net margins, ROE, and ROA, and a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

September 27, 2024 | 5:01 pm

MEDP

Medpace Holdings (NASDAQ:MEDP) has received mixed ratings from 9 analysts, with a recent decline in average price targets. Analysts have adjusted their ratings and price targets, reflecting changing market conditions. Despite this, Medpace shows strong financial performance with impressive revenue growth, net margin, and return on equity.

Portfolio Pulse from Benzinga Insights

September 27, 2024 | 5:00 pm

GGG

Graco (NYSE:GGG) has received mixed analyst ratings over the last quarter, with a recent average price target of $85.0, slightly down from $86.75. Analysts have adjusted their ratings and price targets, reflecting a cautious outlook. Graco's financials show strong profitability and efficient asset management, but recent revenue growth has been challenging.

Portfolio Pulse from Benzinga Insights

September 27, 2024 | 5:00 pm

BLNK

WBAT

Blink Charging Co. (NASDAQ:BLNK) shares rose after surpassing 100,000 EV chargers sold, deployed, or contracted globally. The company attributes this success to its turnkey model and maintenance programs. Blink plans to lay off 14% of its workforce to cut costs. The stock has a 1-year price target of $5.12, with no bearish analyst recommendations.

Portfolio Pulse from Lekha Gupta

September 27, 2024 | 4:55 pm